COR Cencora, Inc.
USHealthcareAs of 2026-07-10 16:00
Why COR matters now
Cencora, Inc. (COR) is a US stock in Healthcare. The latest InvestLog snapshot shows $303.44 with +0.32% on the session and $59.04B in market capitalization; recent performance reads 1-month +2.13% and YTD -19.52%.
The latest financial table shown here is Q2 2026, with revenue of $78.36B, net income of $1.64B, and EPS of $8.40. Investors can compare that operating picture with valuation signals such as P/E 38.40 and FCF yield 2.9%.
The latest indexable market news headline is "Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $360.00; recent insider activity includes DURCAN DERMOT MARK filing P-Purchase; recent congressional disclosure data includes Jared Moskowitz Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
38.40
PEG
2.34
P/B
15.56
P/S
0.16
EV/EBITDA
12.62
DCF Value
$703.72
FCF Yield
2.9%
Div Yield
0.9%
Margins & Returns
Gross Margin
3.5%
Operating Margin
1.3%
Net Margin
0.8%
ROE
115.9%
ROA
3.1%
ROIC
11.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $78.36B | $1.64B | $8.40 |
| Q1 2026 | $85.93B | $559.6M | $2.87 |
| Q4 2025 | $83.73B | $-339.7M | $-1.75 |
| FY 2025 | $321.33B | $1.55B | $7.96 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$378.57
Target (Median)
$360.00
Target Range
$331.00 - $440.00
Trading Activity
Insider Trades
Congress Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Distribution
Country
US
Exchange
—
Beta
0.59
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.